Genentech announced FDA has accepted the company's supplemental Biologics License Application for Tecentriq (atezolizumab) in combination with Abraxane (albumin-bound paclitaxel; nab-paclitaxel) and carboplatin for the initial treatment of people with metastatic non-squamous non-small cell lung cancer who do not have EGFR or ALK genomic tumor aberrations.
Merck announced the first presentation of results from KEYNOTE-181, a phase III trial investigating Keytruda, an anti-PD-1 therapy, as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Array BioPharma Inc. announced updated safety and efficacy results, including mature overall survival, from the safety lead-in of the phase III BEACON CRC trial evaluating the triplet combination of Braftovi (encorafenib), a BRAF inhibitor, Mektovi (binimetinib), a MEK inhibitor and Erbitux (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer.
LUNGevity has issued a Request for Applications for translational research for Career Development Awards that will be granted in 2019. The RFA is available on the LUNGevity website and is also posted on the proposalCENTRAL website.
Wasif Saif, Louis Potters, Matthew Weiss named deputy physicians in chief at Northwell Health Cancer
Wasif SaifMatthew WeissLouis PottersThe Northwell Health Cancer Institute has revamped its clinical leadership structure as part of an expansion of services, appointing three deputy physicians-in-chief to lead medical, surgical and radiation oncology across the 23-hospital health system.
Duke Cancer Institute has partnered with Teen Cancer America and Raleigh, N.C.-headquartered First Citizens Bank to enhance its services for teenagers and young adults with cancer.
Adi Gazdar, a pathologist and a noted oncology researcher at UT Southwestern Medical Center, died on Dec. 29, 2018. He was 81.
On Jan. 2, my friend and long-time mentor Waun Ki Hong passed away. In thinking about what Ki did for me personally and the impact he had on the lives and professional careers of so many people, I pulled out a speech I gave at his retirement celebration at MD Anderson on Aug. 15, 2014. I was struck that even in his passing so many of my thoughts ring true today. Perhaps this will give readers of The Cancer Letter a sense of the man.
An internal task force formed to investigate conflicts of interest at Memorial Sloan Kettering Cancer Center has produced three initial recommendations that codify the moratoria that were put in place after multiple ethics transgressions at the cancer center were revealed by The New York Times and ProPublica last fall.
Thomas Jefferson University is vying to acquire Fox Chase Cancer Center from its current owner, Temple University, the two institutions announced Jan. 10.
